3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Precancerous Conditions
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Tongue Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Brain Neoplasms
1
Bile Duct Neoplasms
1
Basal Cell Nevus Syndrome
1
Interventions
Imiquimod
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Flow Cytometry
2
Conization
2
Colposcopy
2
Biopsy
2
poly ICLC
1
motexafin lutetium
1
human papillomavirus vaccine, TA
1
Zoledronic Acid
1
Vaccines, DNA
1
Vaccines
1
Transcription Activator-Like Effector Nucleases
1
Sodium Chloride
1
Polymerase Chain Reaction
1
Photochemotherapy
1
Microarray Analysis
1
Interferon alpha-2
1
Immunohistochemistry
1
Hysterectomy
1
Fluorescent Antibody Technique
1
Fenofibrate
1
Curcumin
1
Chemoradiotherapy
1
CRISPR-Associated Protein 9
1
Blood Specimen Collection
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Uterine Cervical Dysplasia
×
Microarray Analysis
×
Clear all
NCT00629577
2017-02-01
SAGE
British Columbia Cancer Agency
Phase 1
Terminated
50 enrolled